Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors …

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet
twitter: 11 X users

bluesky: 1 Bluesky user

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 13 X posts from 11 X users, with an upper bound of 58,812 followers.

RT @Dr_R_Kurzrock: DART hits the rare cancers target over and over. Nivolumab plus ipilumumab in PECOmas 🎯🎯 https://t.co/c4PlzRtr8x https:…

DART hits the rare cancers target over and over. Nivolumab plus ipilumumab in PECOmas 🎯🎯 https://t.co/c4PlzRtr8x https://t.co/P94AGGp3RV

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.